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Abstract  
            Pacing prevention algorithms have been introduced in order to maximize the benefits of 
atrial pacing in atrial fibrillation prevention. It has been demonstrated that algorithms actually 
keep overdrive atrial pacing, reduce atrial premature contractions, and prevent short-long atrial 
cycle phenomenon, with good patient tolerance. However, clinical studies showed inconsistent 
benefits on clinical endpoints such as atrial fibrillation burden. Factors which may be 
responsible for neutral results include an already high atrial pacing percentage in conventional 
DDDR, non-optimal atrial pacing site and deleterious effects of high percentages of apical 
ventricular pacing. Atrial antitachycardia pacing (ATP) therapies are effective in treating 
spontaneous atrial tachyarrhythmias, mainly when delivered early after arrhythmia onset and/or 
on slower tachycardias. Effective ATP therapies may reduce atrial fibrillation burden, but 
conflicting evidence does exist as regards this issue, probably because current clinical studies 
may be underpowered to detect such an efficacy. Wide application of atrial ATP may reduce the 
need for hospitalizations and electrical cardioversions and favorably impact on quality of life. 
Consistent monitoring of atrial and ventricular rhythm as well as that of ATP effectiveness may 
be   extremely   useful   for   optimizing   device   programming   and   pharmacological   therapy.
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Introduction
               Atrial fibrillation is surely the most common arrhythmia in clinical practice and 
nowadays its incidence is increasing mainly due to the progressive ageing of population. Atrial 
fibrillation represents also the cardiac rhythm disorder that causes the highest number of 
hospitalizations1 and is associated with higher mortality2, major clinical complications such as 
heart  failure,   acute  myocardial   infarction,  stroke3,   and  impaired  quality  of   life4.   Atrial 
fibrillation is frequently associated with ventricular tachyarrhythmias. It has been calculated that 
20% of the patients with conventional indication for cardioverter defibrillator implantation had 
atrial fibrillation before implant and that during the lifespan of the device more than 50% may 
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develop atrial fibrillation5,6. Antiarrhythmic drugs have been widely used for cardioversion and 
maintenance of sinus rhythm, but they showed a limited and usually temporary efficacy7. As a 
consequence, several non-pharmacological therapies, including physiological pacing, pacing 
prevention algorithms, anti-tachycardia pacing therapies and low-energy internal cardioversion 
have  been  introduced   to   treat  drug   refractory   patients   and   have   been   implemented   in 
multifunction implantable  devices8.                                                                          
Pacing prevention algorithms                                                                                             
               Antiarrhythmic benefits of atrial and dual-chamber pacing versus single-chamber 
ventricular pacing in reducing atrial fibrillation recurrences and in preventing progression to 
permanent atrial fibrillation have been clearly demonstrated in large prospective trials enrolling 
either sinus node disease patients or unselected patients candidate for pacemaker implantation9-
11. It has also been suggested that availability of rate responsiveness may maximize the effect of 
physiological pacing12. Pacing prevention algorithms have been introduced in order to maximize 
the preventive benefits of atrial pacing. Specific mechanisms involved in atrial fibrillation 
prevention   by   pacing   algorithms   include   premature   atrial   contraction   suppression   or 
conditioning, with fewer chances to initiate atrial fibrillation, short-long atrial cycle prevention 
and maintenance of a high degree of exit block from all natural subsidiary atrial pacemakers. 
Several algorithms have been introduced by the different manufacturers during the last years. To 
summarize, they may be classified as follows: 1) dynamic sinus rhythm overdrive, 2) premature 
atrial beat reaction (short-long cycle prevention and ectopy overdrive), 3) post-tachycardia 
overdrive to prevent early recurrence of atrial fibrillation, and 4) prevention of inappropriate 
rate fall after exercise. The atrial pacing preference algorithm was the first evaluated, before 
being implemented in market released devices, as a temporary software, named "consistent 
atrial pacing", which could be downloaded into a conventional dual-chamber pacemaker via 
telemetry using a custom research telemetry device. It included a diagnostic which could be 
interpreted by a special Microsoft Excel spreadsheet. Diagnostic data were available also when 
the algorithm was switched off (suspended). The reliability and effectiveness of such algorithm 
was evaluated in a prospective randomized pilot study in which 61 patients with brady-tachy 
syndrome were enrolled and implanted with a rate responsive dual-chamber pacemaker13. After 
downloading of the algorithm, patients were randomly assigned to algorithm programming "on" 
or "suspended", with crossover after 1 month. Consistent atrial pacing induced an increase in 
atrial pacing percentage from 77 to 96%, and was associated with an 80% reduction of 
premature atrial contractions' number. Atrial fibrillation recurrences were not reduced in the 
overall population, but they significantly decreased by 42% when considering the patients in 
whom the atrial pacing percentage was < 90% during the algorithm "suspended" period. 
Algorithm tolerance was good with no severe adverse events. The atrial rate stabilization 
algorithm has been evaluated (alone or combined with consistent atrial pacing) in 16 patients 
with brady-tachy syndrome14. With regard to the effects on atrial fibrillation burden, 11 patients 
(69%) were found to benefit significantly from the consistent atrial pacing or atrial rate 
stabilization algorithms (reduction > 50% of atrial fibrillation burden). In detail, 7 patients were 
responders to both algorithms, 2 to consistent atrial pacing only, and 2 to atrial rate stabilization 
only.
            The ability of the post-mode switching overdrive algorithm to stabilize the atrial rate 
after termination of treated atrial arrhythmias has been studied in 15 patients with structural 
heart disease and documented atrial and ventricular arrhythmias, receiving a Jewel AF device15. 
The algorithm was active in 41% of 600 spontaneous atrial tachyarrhythmia episodes. It was 
capable of driving and stabilizing the atrial rhythm in the presence of slow spontaneous atrial 
rhythm or premature atrial beats with normal atrioventricular conduction. In case of premature 
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atrial beats with any degree of atrioventricular block, the algorithm stabilized the ventricular 
rate. The authors concluded that the algorithm is reliable and might be of benefit for atrial 
arrhythmia   treatment.                                                                              
            Efficacy of preventive pacing algorithms has been confirmed by the preliminary results 
of the AF Therapy Study16. In 97 patients with a history of paroxysmal atrial fibrillation of at 
least 1 year, who had experienced at least three episodes during the last 3 months and were 
refractory to drug therapy, activation of four different preventive algorithms was associated with 
a significant improvement in all pre-selected endpoints: atrial fibrillation burden, average sinus 
rhythm duration, mean time in-between atrial arrhythmia episodes and number of patients free 
of atrial arrhythmias lasting > 1 min. All benefits were observed either in patients with or 
without conventional indication for pacing. Similarly, in the ADOPT trial17, in which 320 
patients were enrolled in a parallel design with randomization to algorithms on vs. off, 
symptomatic atrial fibrillation burden was reduced by 25% in the treatment group. On the 
contrary, atrial fibrillation episode number, quality of life and hospitalizations did not differ 
between the two randomization arms. An important criticism of ADOPT trial was that only 
symptomatic AF was used as an end-point.                                                                                         
            Also, a retrospective analysis by the ADOPT investigators presented in Heart Rhythm 
2004 suggested that less ventricular pacing  is associated with less AF recurrence (although the 
results did not reach statistical significance). Concern about the actual effectiveness of 
prevention algorithms in improving clinical outcome has been raised by the conflicting 
results18,19  of the most recently published studies in which arrhythmia burden was usually 
selected as the main endpoint. To explain that, the interaction with other critical factors has been 
claimed, first of all the atrial pacing site. It is well known that atrial pacing from the right atrial 
appendage is associated with a prolonged P wave duration with unfavorable effects on atrial 
conduction and refractoriness. Clinical studies suggest that combining prevention algorithms 
with   interatrial   septal   pacing   may   lead   to   better   clinical   outcome20.   Furthermore,   the 
hemodynamic negative effects of unnecessary ventricular pacing in dual-chamber pacing 
systems   may   counterbalance   the   preventive   role   of   pacing   algorithms.   Blanc   et   al.21 
demonstrated that pacing algorithms could reduce the atrial arrhythmia burden only in patients 
with ventricular pacing percentage < 70%. In the MOST study22, in patients with sinus node 
disease,   atrial   fibrillation   recurrences   had   reverse   relationship   with   ventricular   pacing 
percentage. Moreover, the OASES trial23 showed that the AF Suppression algorithm was even 
more effective when the atrial lead was implanted in the low atrial septum. In patients with right 
atrial appendage leads, the algorithm reduced AF burden as measured by mode-switches by 
49%, whilst in patients with low atrial septal leads, the AF burden was reduced by 70%. 
However, whereas the ADOPT and OASES trials showed that this AF suppression algorithm 
reduces AF, trials testing other algorithms have not shown a similar efficacy. The ATTEST 
trial24 evaluated the efficacy of overdrive pacing, and high-rate pacing algorithms in patients 
with AF and an indication for pacing. There were no statistically significant differences in 
recurrence of symptomatic AF or in AF burden. ATP terminated 54% of atrial tachycardia 
episodes, but high-frequency pacing could not terminate AF. Another subsequent trial, quite 
similar   to   OASES   one,   the   ASPECT25,   showed   that   pacing   from   the   atrial   septum 
resynchronizes the atrium and provides an antiarrhythmic effect that enhances the efficacy of 
the suppression algorithms.                                                                                           
            It is very important to recognize the differences between these trials. The ADOPT17 and 
OASES trials23 tested the efficacy of a single algorithm to prevent AF, whereas ATTEST24 
tested the efficacy of 3 preventive pacing algorithms and 2 pacing algorithms designed to 
terminate atrial tachyarrhythmias. Moreover, the follow-up in ATTEST trial was 3 and not 6 
months. Another matter with the OASES and the ASPECT trials was the crossover design. 
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Because the beneficial effect of atrial pacing may persist, this design may have limited the 
observed efficacy of the pacing algorithms. Thus the difference in results between these trials 
may reflect differences in study design or differences in the efficacy of the algorithms used.  
Finally, due to high variability of atrial fibrillation recurrence patterns26, published studies may 
be underpowered to demonstrate the true benefits of prevention algorithms.                     
   
               In summary, 2 trials have shown that AF suppression algorithms enhances the 
antiarrhythmic effects of atrial pacing in patients with AF and an indication for pacing. Thus, 
minimizing ventricular pacing and placing the atrial lead in the septum may probably enhance 
the   efficacy   of   these   algorithms.                                                        
Atrial antitachycardia pacing to treat atrial tachyarrhythmias                              
            It has been demonstrated that rapid atrial pacing delivered for treating atrial tachycardia 
or atrial flutter may be effective in restoring sinus rhythm  in 60-90% of patients27. Maximal 
effectiveness can be usually obtained by delivering antitachycardia pacing at a rate that is 
slightly greater than the atrial arrhythmia rate. Delivering of some extrastimuli following a rapid 
pacing train may be more efficacious than overdrive atrial pacing at the same pacing cycle 
length in terminating atrial flutter28. High-frequency pacing may change atrial tachycardia in 
transient atrial fibrillation with later sinus rhythm restoration. Appropriate detection of atrial 
tachyarrhythmias and efficacy of pacing therapies in patients receiving a dual defibrillator have 
been evaluated in large series. Adler et al.29 reported on 537 patients with ventricular arrhythmia 
implanted with the Medtronic 7250 dual defibrillator (Medtronic Inc., Minneapolis, MN, USA) 
who were enrolled in the Worldwide Jewel AF Study and followed on average for 1 year. 
Seventy-four percent had a documented history of prior atrial tachyarrhythmias. Seventy-one 
percent of the patients had atrial therapies enabled at some time during the follow up, allowing 
collection and analysis of 3500 atrial episodes from 167 patients. In the 7250 Dual Defibrillator 
Italian   Registry30,   105   patients   were   enrolled.   Implant   indication   was   represented   by 
combination   of   ventricular   and   atrial   tachyarrhythmias   in   52%   of   patients,   ventricular 
tachyarrhythmias only in 33%, and atrial tachyarrhythmias only in 14%. During a mean follow-
up of 6 months, 863 treated atrial episodes were collected and analyzed. Gold et al.31, on behalf 
of the Worldwide Jewel AF-Only Investigators, studied 146 patients with recurrent drug 
refractory atrial fibrillation without prior ventricular tachyarrhythmias, who were implanted 
with a dual defibrillator and were followed on average for 1 year. During the follow-up 4913 
treated episodes were available for stored electrogram analysis and therapy efficacy evaluation. 
Atrial tachyarrhythmia detection was very good in all the studies with a positive predictive 
value of atrial detection ranging from 91 to 99%. The most common reasons of inappropriate 
detection were represented by far-field R-wave oversensing during sinus rhythm or cluster of 
premature atrial contractions. Reprogramming of atrial sensitivity allowed in some case 
avoidance of inappropriate detection due to far-field R-wave oversensing. Sensitivity of atrial 
tachycardia   and   fibrillation   detection   and   validation   of   continuous   detection   of   atrial 
tachyarrhythmias have been specifically addressed by Swerdlow et al.42  who performed 80 
Holter recordings with telemetered atrial electrograms in 58 patients, implanted because of 
combination   of   atrial   and   ventricular   arrhythmias.   Continuous   detection   of   atrial 
tachyarrhythmia could be demonstrated in 96% of patients with spontaneous episodes. Atrial 
sensitivity for arrhythmia detection was 100%. It is worthwhile to stress that the atrial 
arrhythmia detected at very early onset was very commonly a well organized atrial tachycardia. 
Among 2380 episodes in the worldwide series, 63% were classified as atrial tachycardia (mean 
atrial cycle 278 ± 56 ms) and 37% as atrial fibrillation (mean cycle 204 ± 35 ms). In the Italian 
Registry, among 863 atrial episodes, 53% were automatically classified by the device as atrial 
tachycardia and 47% as atrial  fibrillation. After  revision  of  the stored  data,  among  843 
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appropriately detected episodes, 55% were clinically classified as atrial fibrillation and 45% as 
atrial tachycardia. In the AF-Only group, among 3116 episodes treated by antitachycardia 
pacing, 67% were classified as atrial tachycardia.                                                                   
            Efficacy of antitachycardia pacing therapy in the three series is reported in Table 129-31. 
The efficacy was estimated in two ways: 1) crude estimate, defined as the proportion of 
successful terminations out of the total number of treated episodes; 2) adjusted estimate, using 
the generalized estimate equation method30  which allows adjusting estimate for multiple 
episodes within a patient through a correlation structure between episodes and patients.
Table 1:  Efficacy of antitachycardia pacing on spontaneous atrial tachyarrhythmias (AE = 
Adjusted Estimate; CE = Crude Estimate; CI = Confidence Interval).
            In the worldwide study29-31, a subanalysis performed to compare the efficacy of burst+ 
vs. ramp therapy for atrial tachycardia did not find any significant difference between the two 
therapies. An history of atrial flutter was the only independent predictor of pacing efficacy for 
atrial tachycardia, while no independent predictors could be identified for atrial fibrillation. No 
comparison was feasible between burst+ or ramp and high-frequency burst because the last was 
usually   applied   after   unsuccessful   delivery   of   burst+   or   ramp   therapy.
               Pooling all antitachycardia pacing therapies (burst+, ramp and 50 Hz burst), their 
efficacy consistently increased as far as atrial arrhythmia cycle lengthened. As a matter of fact, 
in the Italian Registry, while the relationship between efficacy of atrial burst+ and ramp vs. 
atrial cycle length was very high (r2 = 0.85, p < 0.001), the relationship between efficacy of 50 
Hz burst and atrial cycle length was very poor, with a trend toward a reverse correlation (r2 = 
0.31, p < 0.05). Such a difference could be explained by taking into account the mechanisms of 
action of different antitachycardia pacing techniques. During overdrive pacing, the wavefront of 
pacing stimulus enters the reentrant pathway in the antidromic and orthodromic direction. The 
antidromic wavefront blocks by collision the arrhythmia wavefront, while the orthodromic 
wavefront may either reset the tachycardia or stop it, when early enough to be blocked in a 
refractory area. Slower tachycardias, due to  a wider  excitable  gap,  may  be  more  easily 
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terminated in this way. Termination of atrial tachyarrhythmias by high-frequency pacing is 
typically preceded by tachycardia acceleration, which becomes unable to be sustained, hence 
resulting in arrhythmia termination and sinus rhythm restoration. It has been hypothesized that 
high-frequency pacing induces a new faster reentrant circuit which is unable to sustain itself34. 
This mechanism looks independent of the arrhythmia cycle.                                         
            Looking at individual patients, random and wide distribution of median atrial cycles at 
onset during the follow-up was observed in the majority of them. A subgroup showed a narrow 
Gaussian distribution along either a fast (200 ms) or a slow band (250 ms). Antiarrhythmic 
drugs have been demonstrated to be capable of modifying atrial cycle profile. Antiarrhythmics 
may modify the electrophysiological properties of the atria and the arrhythmia organization 
pattern by lengthening the mean atrial arrhythmia cycle and by widening the temporal excitable 
gap35-37. Dijkman and Wellens38 demonstrated that atrial arrhythmias in defibrillator patients 
with structural heart disease, receiving class III antiarrhythmic drugs, frequently had longer 
cycle lengths than atrial fibrillation. In fact, among 600 spontaneous episodes, atrial fibrillation 
was diagnosed in 19%, fast polymorphic atrial tachycardia in 20%, fast monomorphic atrial 
tachycardia in 57%, and slow atrial tachycardia in 4%. Drug-induced atrial cycle length changes 
may impact on atrial antitachycardia pacing therapy efficacy. In spite of that, in the AF-Only 
series there were no drugs that were independent predictors of therapy efficacy.                 
               Finally, increasing the delay from arrhythmia detection to therapy delivery was 
associated with a significant reduction in efficacy. Optimal delay has been identified in less than 
5 min in the Worldwide Study and in less than 1 min in the Italian Registry. That was probably 
due to the fact that the majority of atrial tachyarrhythmias accelerated in few minutes after 
onset. Considering that slower arrhythmias can be more easily treated by pacing techniques, a 
short delay in therapy delivery should be recommended. The efficacy of 50 Hz burst on atrial 
fibrillation may be a matter of debate. Wide local capture of atrial fibrillation has been 
documented39. Data from canine studies suggested that high-frequency pacing could accelerate 
the local atrial fibrillation cycle length and destabilize the reentrant rhythm so that destabilized 
atrial fibrillation could be converted to sinus rhythm in some cases. Anyway, in humans 
termination   of   persistent   atrial   fibrillation   by   high-frequency   pacing   could   never   be 
demonstrated40-41. High-frequency pacing may terminate induced atrial fibrillation during 
electrophysiological study with a 33% efficacy rate34  and atypical atrial flutter with a 60% 
efficacy rate41. In selected cases, local capture of new-onset atrial fibrillation and entrainment of 
a relatively large area of the atria42 could have destabilized the arrhythmia by reducing the 
number of wavelets of the random reentry, hence preventing  arrhythmia  sustenance. Anyway, 
considering  that  arrhythmia  classification  is  based  on  atrial  activity  at  atrial  lead  site, 
misclassification of atrial tachycardia as atrial fibrillation cannot not be excluded. Furthermore, 
some episodes may have terminated spontaneously after therapy delivery43.                   
            The ASPEN-ICD and ASSIST trials will probably give more data about these new 
perspectives. They will test the algorithm in  patients with ICDs. The former will determine if 
the first episodes of AF can be prevented by the algorithm, whereas the latter will test if this 
algorithm prevents AF in patients who have a history of atrial arrhythmia.                             
 
            Safety of antitachycardia pacing therapy was excellent since no ventricular arrhythmia 
induction was observed in any case after antitachycardia pacing delivery. These data suggest 
that, on a large scale, these algorithms would presumably be safe, and that it would be necessary 
to better determine how effective atrial ATP is, and whether it would reduce hispitalizations 
and/or   electrical   or   pharmacological   cardioversions   and   thereby   improve   quality-of-life.
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Conclusions
            As stated in the discussed trials, pacing prevention algorithms should probably be better 
and further evaluated, before having a definitive and comprehensive answer on their utility. 
Clinical studies showed inconsistent clinical benefits of the algorithms, although they reduce 
atrial fibrillation triggers such as premature atrial complexes, thus preventing short-long cycle 
phenomenon. Factors which may be responsible for neutral results include: 1) high atrial pacing 
percentage in conventional DDDR, 2) non-optimal atrial pacing site, 3) deleterious effects of 
high percentages of ventricular pacing, and 4) inappropriate study design and endpoint 
selection. Variability of atrial arrhythmia recurrence patterns and onset mechanisms suggest 
individual programming of prevention algorithms by using data stored in the device memory. 
Atrial antitachycardia pacing is an effective tool to treat atrial tachyarrhythmias and it may stop 
nearly 50% of arrhythmia episodes. In particular, all previously described data are more related 
to atrial tachycardia reduction than to atrial fibrillation decrease. Delivery of atrial therapies 
early after arrhythmia onset and on more organized arrhythmias may improve success rate. 
Associated use of antiarrhythmic drugs, mainly propafenone and flecainide, may further 
increase effectiveness by lengthening atrial arrhythmia cycle.                                   
             Effective antitachycardia pacing therapies may reduce atrial fibrillation burden, but 
conflicting evidence does exist as regards this issue, probably because current clinical studies 
may be underpowered to detect such an efficacy. Consistent monitoring of atrial and ventricular 
rhythm as well as that of antitachycardia pacing effectiveness may be extremely useful for 
optimizing device programming and pharmacological therapy. At present the efficacy of pacing 
algorithms to prevent AF is by no means something that has been proved beyond reasonable 
doubt, so that more large-scale prospective trials are needed to answer this question. Our 
information is currently based on small trials and any attempt to extrapolate these data to the 
general population will probably produce inaccurate results. Clinical endpoints should be further 
investigated   in  future  studies.                                                                               
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